FDA-Cleared Test Detects Carbapenem Resistance Genes
By LabMedica International staff writers Posted on 21 Mar 2016 |
A qualitative in vitro diagnostic test for fast, accurate, and reproducible identification of five distinct families of carbapenem resistance genes that together represent the most common carbapenemases has been approved for marketing.
The test is for the detection and differentiation of carbapenemase genes in pure bacterial isolates, previously shown to be non-susceptible to carbapenem antibiotics, which may be cultured from a wide range of clinical specimens, including blood cultures, urine, respiratory samples, abscesses and swab surveillance specimens.
The test, known as Xpert Carba-R (Cepheid; Sunnyvale, CA; USA) has received clearance from the US Food and Drug Administration (FDA; Silver Springs, MD, USA) for marketing. The five distinct families of carbapenem resistance genes identified include Klebsiella pneumoniae carbapenemase (KPC), New Delhi metallo-beta-lactamase (NDM), Vimentin (VIM), OXA-48 Carbapenemase (OXA-48) and, the metallo-beta-lactamase “active on imipenem” gene (IMP-1). Xpert Carba-R will begin shipping in the USA later this month, and is the 20th US-IVD test available to run on Cepheid's GeneXpertSystem, the world's leading molecular diagnostic platform with more than 10,000 systems installed globally. Xpert Carba-R is the latest diagnostic solution from Cepheid to help infection control professionals fight antimicrobial resistance, building on their portfolio.
Paul Schreckenberger, PhD, Director of Microbiology at Loyola University Medical Center (Maywood, IL, USA), said, “The availability of a rapid and accurate molecular test for the most prevalent mechanisms of carbapenem resistance represents an important addition to the limited tools the laboratory has available to fight the emergence of multidrug resistant organisms, like carbapenemase producing organisms (CPOs). Knowing which carbapenemase gene is present in a resistant isolate helps the hospital identify and manage outbreaks and can also be valuable for monitoring the spread of multi-resistant bacteria among hospital populations considered most at risk. Xpert Carba-R delivers a result in under an hour, allowing timely detection and differentiation of the most prevalent carbapenemase genes associated with CPO outbreaks to support infection control efforts.”
Related Links:
Cepheid
US Food and Drug Administration
Loyola University Medical Center
The test is for the detection and differentiation of carbapenemase genes in pure bacterial isolates, previously shown to be non-susceptible to carbapenem antibiotics, which may be cultured from a wide range of clinical specimens, including blood cultures, urine, respiratory samples, abscesses and swab surveillance specimens.
The test, known as Xpert Carba-R (Cepheid; Sunnyvale, CA; USA) has received clearance from the US Food and Drug Administration (FDA; Silver Springs, MD, USA) for marketing. The five distinct families of carbapenem resistance genes identified include Klebsiella pneumoniae carbapenemase (KPC), New Delhi metallo-beta-lactamase (NDM), Vimentin (VIM), OXA-48 Carbapenemase (OXA-48) and, the metallo-beta-lactamase “active on imipenem” gene (IMP-1). Xpert Carba-R will begin shipping in the USA later this month, and is the 20th US-IVD test available to run on Cepheid's GeneXpertSystem, the world's leading molecular diagnostic platform with more than 10,000 systems installed globally. Xpert Carba-R is the latest diagnostic solution from Cepheid to help infection control professionals fight antimicrobial resistance, building on their portfolio.
Paul Schreckenberger, PhD, Director of Microbiology at Loyola University Medical Center (Maywood, IL, USA), said, “The availability of a rapid and accurate molecular test for the most prevalent mechanisms of carbapenem resistance represents an important addition to the limited tools the laboratory has available to fight the emergence of multidrug resistant organisms, like carbapenemase producing organisms (CPOs). Knowing which carbapenemase gene is present in a resistant isolate helps the hospital identify and manage outbreaks and can also be valuable for monitoring the spread of multi-resistant bacteria among hospital populations considered most at risk. Xpert Carba-R delivers a result in under an hour, allowing timely detection and differentiation of the most prevalent carbapenemase genes associated with CPO outbreaks to support infection control efforts.”
Related Links:
Cepheid
US Food and Drug Administration
Loyola University Medical Center
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia